Vistagen Awarded Mental Health America’s Platinum Bell Seal for Workplace Mental Health
May 24 2023 - 8:30AM
Business Wire
Mental Health America’s prestigious national
certification complements Vistagen’s ongoing efforts to improve
mental health care across the U.S.
Timely recognition comes during Mental Health
Awareness Month and MHA’s nationwide efforts to fight stigma and
provide support around mental health
Vistagen (NASDAQ: VTGN), a late clinical-stage biopharmaceutical
company aiming to transform the treatment landscape for individuals
living with anxiety, depression and other central nervous system
(CNS) disorders, today announced that it has been recognized by
Mental Health America (MHA) for its commitment to fostering mental
health and well-being in the workplace. Vistagen’s supportive
workplace culture, mental health care benefits, focus on inclusion,
and wellness programs have earned it MHA’s Platinum Bell Seal for
Workplace Mental Health, MHA’s highest award for comprehensive
workplace mental health support.
“Our commitment to improving the trajectory of global mental
health starts in our own company,” said Shawn Singh, Chief
Executive Officer of Vistagen. “As we strive to develop
transformative medicines for patients suffering from anxiety,
depression and other mental health disorders, we prioritize
supporting our employees’ mental health and well-being, both inside
and outside of our workplace. May is Mental Health Awareness Month,
an important time each year to elevate important issues involving
mental health and encourage further progress in discussing,
recognizing, and treating mental health disorders. We thank Mental
Health America for acknowledging our commitment to our team’s
mental health, an essential factor in our team’s ability to remain
laser-focused on achieving our mission.”
MHA’s Platinum Bell Seal certification, and Vistagen’s ongoing
development of innovative mental health medicines, come as the
United States grapples with a mental health epidemic exacerbated by
pandemic-related isolation, as well as a new advisory from the U.S.
Surgeon General on the disastrous mental health outcomes associated
with social isolation and loneliness. Vistagen's leading-edge
workplace mental health policies and programs aim to give its
employees the time and resources they need to care for their mental
health and foster a positive workplace culture through team
building, flexible work arrangements, and a commitment to diversity
and inclusion.
About MHA’s Bell Seal for Workplace Mental Health
The Bell Seal for Workplace Mental Health national certification
program recognizes employers committed to creating mentally healthy
workplaces. Led by MHA’s rich history in research and advocacy, the
Bell Seal's holistic evaluation of employer practices considers the
entire employee experience. In collaboration with the U.S.
Department of Labor, U.S. Centers for Disease Control and
Prevention and national companies, MHA is committed to furthering
worker safety, health, and well-being alongside leading health and
advocacy organizations. Bell Seal recognition builds a sense of
pride in employers and optimism in existing and prospective
employees alike. Qualifying organizations are recognized at
different levels – bronze, silver, gold or platinum – and are
assessed based on how mental health is approached via four
categories: workplace culture, benefits, compliance and wellness
programs.
About Vistagen
Vistagen (Nasdaq: VTGN) is a late clinical-stage
biopharmaceutical company aiming to transform the treatment
landscape for individuals living with anxiety, depression and other
CNS disorders. Vistagen is advancing therapeutics with the
potential to be faster-acting, and with fewer side effects and
safety concerns, than those that are currently available for
treatment of anxiety, depression and multiple CNS disorders.
Vistagen’s pipeline includes six product candidates, including five
clinical-stage investigational agents belonging to a new class of
drugs known as pherines, in addition to AV-101, an oral antagonist
of the glycine site of the N-methyl-D-aspartate receptor (NMDAR).
Pherines, which are administered as nasal sprays, are designed with
an innovative rapid-onset mechanism of action that activates
chemosensory neurons in the nasal passages and can selectively and
beneficially impact key neural circuits in the brain without
requiring systemic uptake or direct activity on CNS neurons.
Vistagen’s AV-101 inhibits activity of the ion channel of the NMDAR
but does not block it. Vistagen is passionate about transforming
mental health care and redefining what is possible in the treatment
of anxiety, depression and several other CNS disorders. Connect at
www.Vistagen.com.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20230524005380/en/
Media: Nate Hitchings SKDK nhitchings@skdknick.com
Investors: Mark McPartland Senior Vice President,
Investor Relations (650) 577-3606 markmcp@vistagen.com
VistaGen Therapeutics (NASDAQ:VTGN)
Historical Stock Chart
From Apr 2024 to May 2024
VistaGen Therapeutics (NASDAQ:VTGN)
Historical Stock Chart
From May 2023 to May 2024